Peptide Glossary: Key Terms Explained

The language around peptides borrows from four overlapping fields: biochemistry (what a peptide is made of), pharmacology (how it engages the body's receptors), pharmacokinetics (how the body absorbs, distributes, and clears it), and manufacturing science (how it is synthesized and quality-tested). A single product page or research abstract can pull vocabulary from all four at once, which is why the terminology feels dense.

This glossary defines the terms you are most likely to meet, grouped by theme rather than strictly alphabetically, so that related ideas sit next to each other. Each entry is one or two sentences. Where a term has a precise technical meaning, we give that meaning rather than a loose approximation.

A note on scope: this is a definitions reference, not a how-to guide. It does not recommend, dose, or explain how to prepare or use any substance. Many peptides discussed in the literature are prescription medicines, investigational compounds, or research chemicals, and are covered here strictly to explain what the words mean.

These terms describe what a peptide physically is and how its structure is written down.

• Amino acid — the basic building block of peptides and proteins; a small molecule with an amino group, a carboxyl group, and a variable side chain. Twenty standard amino acids make up most naturally occurring peptides.

• Peptide — a short chain of amino acids joined together; by common convention chains of roughly 2 to 50 amino acids are called peptides, while longer chains are called proteins. The boundary is a matter of convention, not a sharp rule.

• Peptide bond — the covalent amide bond that links the carboxyl group of one amino acid to the amino group of the next. These bonds form the backbone of the chain and are the sites vulnerable to enzymatic breakdown.

• Residue — a single amino acid unit once it is incorporated into a chain (it has lost a water molecule during bond formation, so it is a residue rather than a free amino acid).

• Sequence — the specific order of amino acid residues in a peptide, usually written from the N-terminus to the C-terminus using one- or three-letter codes. The sequence defines the molecule's identity.

• Primary structure — the amino acid sequence itself, the most basic level of a peptide's structural description.

• N-terminus and C-terminus — the two ends of a peptide chain; the N-terminus carries a free amino group, the C-terminus a free carboxyl group. By convention, sequences are read and numbered starting from the N-terminus.

• Analog (analogue) — a molecule whose structure is deliberately modified from a reference peptide, for example by swapping, adding, or chemically altering amino acids, to change its stability, potency, or selectivity. Many peptide medicines are analogs of a natural hormone.

• Cyclic peptide — a peptide whose chain is joined into a ring rather than left as an open strand, a modification that often improves resistance to breakdown.

• Endogenous — produced naturally within the body; an endogenous peptide such as ghrelin or GLP-1 is one the body itself makes, as opposed to a synthetic version.

• Synthetic — made in a laboratory rather than isolated from a living source. A synthetic peptide can be identical to a natural one or an engineered analog.

These terms describe how a peptide interacts with the body's molecular machinery — the core of how any peptide is proposed to act. Nearly 50 peptide drugs that target G protein-coupled receptors have been approved to date, most for metabolic disease or cancer, which is why this vocabulary appears so often.

• Receptor — a protein, often embedded in a cell's surface membrane, that recognizes a specific signaling molecule and triggers a response inside the cell when that molecule binds.

• Ligand — any molecule that binds to a receptor. A peptide acting as a signal is a ligand; the term is neutral as to whether it activates or blocks the receptor.

• Agonist — a ligand that binds a receptor and activates it, stabilizing the receptor's active shape and switching on downstream signaling. Most approved peptide therapeutics are agonists that mimic a natural signaling peptide.

• Antagonist — a ligand that binds a receptor but does not activate it, instead blocking the natural agonist from binding and thereby dampening the signal.

• Partial agonist — a ligand that activates a receptor only weakly, producing a submaximal response even when it fully occupies the receptor.

• GPCR (G protein-coupled receptor) — the largest family of cell-surface receptors, characterized by seven membrane-spanning segments; they relay signals from outside the cell to inside and are the target of a large share of peptide drugs.

• Biased agonism — the phenomenon where different agonists at the same receptor preferentially switch on some downstream pathways over others (for example G protein versus β-arrestin signaling), an approach used to try to separate desired effects from side effects.

• Allosteric modulator — a molecule that binds a receptor at a site distinct from where the natural ligand binds, tuning the receptor's response up or down rather than switching it on directly.

• Affinity — how tightly a ligand binds its receptor; higher affinity means the ligand binds at lower concentrations.

• Potency — the amount of a substance needed to produce a given effect; a more potent compound achieves the effect at a lower concentration, often summarized by values such as EC50 (the concentration producing half the maximal effect).

• Selectivity — the degree to which a molecule acts on its intended receptor while leaving others untouched; higher selectivity generally means fewer off-target effects.

• Downregulation and desensitization — adaptive responses in which repeated or sustained stimulation causes cells to reduce receptor numbers or receptor responsiveness, blunting the effect over time.

Several specific biological systems come up repeatedly in peptide literature, particularly around metabolism and the growth-hormone axis.

• Secretagogue — a general term for any substance that prompts a gland or cell to secrete something. A growth hormone secretagogue is a compound that increases the release of growth hormone.

• GHRH (growth hormone-releasing hormone) — a hormone made in the hypothalamus that stimulates the pituitary gland to release growth hormone by binding the GHRH receptor, a GPCR.

• GHS-R (growth hormone secretagogue receptor) — a G protein-coupled receptor with seven transmembrane domains whose natural ligand is ghrelin; its activation is linked to growth hormone release, appetite, and effects on glucose and lipid metabolism.

• Ghrelin — a 28-amino-acid peptide made mainly in the stomach; it is the endogenous ligand for the GHS-R and stimulates appetite and growth hormone secretion.

• GLP-1 (glucagon-like peptide-1) — an incretin hormone released from the gut that stimulates insulin secretion and reduces appetite; its receptor is a heavily studied peptide-drug target for metabolic disease.

• Incretin — a class of gut hormones, including GLP-1, that are released after eating and enhance insulin release in response to glucose.

• Peptide hormone — a signaling molecule made of amino acids that the body uses to communicate between tissues; insulin, ghrelin, and GLP-1 are examples.

Where the previous sections cover what a peptide does to the body, these terms cover what the body does to the peptide — and why peptides are often chemically re-engineered.

• Pharmacokinetics (PK) — the study of how a substance is absorbed, distributed, metabolized, and eliminated by the body over time.

• Pharmacodynamics (PD) — the study of the effects a substance has on the body and the mechanisms behind those effects; the complement to pharmacokinetics.

• Half-life — the time required for the concentration of a substance in the body to fall to half its initial value. After roughly four to five half-lives, a substance following first-order elimination is largely cleared (about 94 to 97 percent gone).

• Bioavailability — the fraction of an administered dose that reaches the bloodstream in active form. Unmodified peptides typically have very poor oral bioavailability because they are broken down in the gut before absorption.

• Proteolysis — the enzymatic breakdown of peptides and proteins by proteases; it is the main reason unmodified peptides often have short half-lives in the body.

• Protease — an enzyme that cleaves peptide bonds, breaking a peptide into fragments.

• Metabolic stability — a peptide's resistance to being broken down (chemically or enzymatically) inside the body; low stability generally means a short half-life.

• PEGylation — attaching polyethylene glycol chains to a peptide to increase its size and shield it, which can substantially extend its circulating half-life.

• Lipidation (fatty-acid acylation) — attaching a fatty acid to a peptide so it binds to blood albumin and circulates longer; this strategy is used in several approved long-acting peptide medicines.

• Subcutaneous — situated or delivered under the skin; a common route for peptide medicines because it avoids the digestive tract. (Described here only to define the term, not as an instruction.)

• First-pass metabolism — the breakdown of a substance by the gut and liver after oral intake, before it reaches general circulation, which reduces the amount that ends up active in the blood.

These descriptors tell you how mature and how transferable a given piece of evidence is — an essential filter for reading peptide claims critically.

• In vitro — literally 'in glass'; experiments performed outside a living organism, such as in cell cultures or test tubes. In vitro results show what is biologically possible but do not prove effects in a whole body.

• In vivo — experiments performed within a living organism, such as in animals or humans. In vivo data is more representative of real physiology than in vitro data but varies by species.

• Preclinical — research conducted before human testing, typically in cells and animals, to explore biology and safety. Preclinical findings frequently do not carry over to humans.

• Clinical — involving human subjects; clinical evidence, especially from controlled trials, sits at the top of the reliability hierarchy for human effects.

• Endogenous versus exogenous — endogenous refers to what the body produces itself; exogenous refers to what is introduced from outside. A synthetic peptide administered to the body is exogenous.

• Mechanism of action — the specific biochemical way a substance produces its effect, for example by acting as an agonist at a named receptor.

• Research chemical — a term often used for substances sold or supplied for laboratory investigation rather than for approved human or veterinary use; regulatory status varies widely by substance and jurisdiction.

These terms describe how a peptide is made and how its identity and quality are verified. They describe production and testing — not how a substance should be handled or used.

• Solid-phase peptide synthesis (SPPS) — the standard laboratory method for building peptides one amino acid at a time on an insoluble resin support, commonly using Fmoc or Boc protective chemistry, then cleaving the finished chain from the resin.

• Lyophilized — freeze-dried; water is removed from a frozen peptide solution under vacuum by sublimation, leaving a dry powder that is generally more stable and easier to store than a solution.

• Reconstitution — the general laboratory concept of dissolving a lyophilized (dried) substance back into liquid. (Defined here only as a term; this glossary gives no preparation instructions.)

• HPLC (high-performance liquid chromatography) — an analytical technique that separates the components of a mixture; reverse-phase HPLC is routinely used to measure a peptide's purity by separating the target molecule from impurities.

• Purity — the proportion of the desired peptide relative to other substances present (excluding moisture and counterions), typically reported as a percentage from HPLC analysis.

• Mass spectrometry (MS) — an analytical technique that measures a molecule's mass to confirm its identity, verifying that the correct amino acids were assembled in the intended sequence.

• Molecular weight — the mass of one molecule, often expressed in daltons (Da); used alongside mass spectrometry to confirm a peptide's identity.

• Certificate of Analysis (COA) — a document from a manufacturer or testing lab reporting the analytical results for a specific batch, such as HPLC purity and mass-spectrometry identity confirmation. A COA describes what testing found for that lot; it is not a safety endorsement or a usage authorization.

• Counterion (TFA / acetate salt) — peptides are often isolated as a salt paired with an ion such as trifluoroacetate (TFA) or acetate left over from synthesis and purification; the counterion form can be noted on analytical documentation.

• Batch (lot) — a discrete quantity of material produced in a single manufacturing run; quality testing and COAs are specific to a batch.

Terminology is only useful if it helps you weigh evidence honestly. A few habits make the vocabulary above more powerful.

Distinguish the tiers of evidence. A striking in vitro or animal result is a hypothesis about humans, not a demonstration in humans. When a claim rests on cell or rodent data, treat it as preliminary, and look for whether controlled human research exists.

Separate pharmacology from pharmacokinetics. A peptide can be a potent agonist at its receptor in a dish yet have almost no effect when taken by mouth because it is destroyed before absorption. Both halves of the picture matter.

Read quality documents for what they are. A Certificate of Analysis tells you whether a specific batch matched an identity and purity specification in the lab. It says nothing about whether a substance is safe, effective, legal, or appropriate to use.

Finally, remember what this reference is and is not. It defines words so you can read the peptide literature with more confidence. It is educational material, not medical advice, and it deliberately contains no dosing, protocols, sourcing, or preparation guidance. For any decision about health, a qualified, licensed professional who knows your situation is the right source.